−1.12USD
−76.24 MUSD
70.14 MUSD
67.27 M
About Codexis, Inc.
Sector
CEO
Stephen George Dilly
Headquarters
Redwood City
Website
Employees (FY)
174
Founded
2002
ISIN
US1920051067
FIGI
BBG000RN0GZ5
Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. The Performance Enzymes segment commercializes CodeEvolver protein engineering technology platform and products in the pharmaceuticals market. The Novel Biotherapeutics segment targets new opportunities to discover and improve biotherapeutic drug candidates. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA.
Promising Long Trade OpportunityHello, traders! Today, I am excited to present a highly promising long trade opportunity that revolves around a bullish order block at $2.29. This trade offers an attractive risk-reward ratio, with a focus on targeting equal highs and capturing potential upward momentum.
Based on careful analysis,
Long Term Buy -(CDXS) Trend Reversal on the Horizon!Today, we're turning our spotlight on Codexis, Inc. (CDXS), a leader in protein engineering. We've been closely observing CDXS and see a potentially exciting opportunity unfolding, and we thought it would be a great time to share our thoughts with you.
Our analysis reveals that CDXS is currently sh
CDXS - upcoming catalystThis is not a financial advice!
Most info on the chart.
Price is at resistance.
We might seeing a pullback first before continuing or we need to break 7 for confirmation. Addtionlly there is a gap.
Trade carefully!
CDXS: Ascending Triangle (64%)Codexis brogr through the 28,80$ resistance once again. This time, it may actually stay above.
Resistance could become support.
Ascending triangle, confirmed!
Price Target = 47.44$
Stay humble, have fun, make money!
CDXS short worked out today 3.8 R3.8 times the initial risk gained on a 5 min breakdown of the 3rd biggest pre-market gainer
$CDXS - May be worth a pre-market buyThis hadn't popped up on my scans, but it is:
1: Sitting on 20ma after decent pullback
2: Sitting on volume shelf
3: Just added by ARKK after hours.
This could fly tomorrow. Might be worth staying up late (1:30am my time) to try to get s good position. I don't think this will be a R3G type of sta
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of CDXS is 2.69 USD — it has decreased by 6.27% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Codexis, Inc. stocks are traded under the ticker CDXS.
Codexis, Inc. is going to release the next earnings report on May 2, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for Codexis, Inc. has a max estimate of 10.00 USD and a min estimate of 3.00 USD.
CDXS earnings for the last quarter are −0.50 USD whereas the estimation was −0.32 USD which accounts for −54.18% surprise. Estimated earnings for the next quarter are −0.12 USD. See more details about Codexis, Inc. earnings.
Codexis, Inc. revenue for the last quarter amounts to 9.28 M USD despite the estimated figure of 10.03 M USD. In the next quarter revenue is expected to reach 19.90 M USD.
Yes, you can track Codexis, Inc. financials in yearly and quarterly reports right on TradingView.
Like other stocks, CDXS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Codexis, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 16, 2024, the company has 174.00 employees. See our rating of the largest employees — is Codexis, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Codexis, Inc. EBITDA is −44.88 M USD, and current EBITDA margin is −63.98%. See more stats in Codexis, Inc. financial statements.